“As a reminder, we continue to target 2026 for a commercial launch.”

In context

“ected with an earlier line trials in a potentially curative setting, it will be several years before we are able to provide an update. We also remain focused on clinical execution of our five other ongoing Phase III programs for Trodelvy and domvanalimab across lung, endometrial and upper GI cancers. Moving to Slide 19. And on behalf of Cindy and the Kite team, we were pleased to present new data from across our cell therapy pipeline at the ASCO and EHA Congresses. In partnership with Arcellx, data from the iMMagine-1 trial at EHA demonstrated the consistent and compelling efficacy and safety profile of anito-cel. We continue to believe anito-cel has the potential to offer a best-in- class profile, and we look forward to presenting pivotal data from this trial towards the end of the year. As a reminder, we continue to target 2026 for a commercial launch. From our next-generation construct at ASCO, we presented initial data from the bicistronic CD19, CD20, Kite-363 CAR T, which we believe has shown a promising profile in B-cell malignancies, and we have selected Kite-363 to be evaluated in Phase I trials of autoimmune and neuroinflammatory conditions. In the second half of this year, we will decide which program to advance in hematology, choosing between our 3 next-generation CAR T constructs. Additionally, in collaboration with the University of Pennsylvania, Perelman School of Medicine, ASCO data on the bicistronic EGFR-IL13Ra2 CAR T strengthens proof-of-concept for expanding CAR Ts to treat solid tumors. Overall, we remain excited in the potential of our next-generation therapies to offer improved efficacy and safety profiles and to rea”